XML 43 R36.htm IDEA: XBRL DOCUMENT
v3.24.3

Segment Information (Tables) | 9 Months Ended
--- | ---
Sep. 30, 2024
Segment Reporting [Abstract] |
Schedule of Financial Information by Segment | Financial information by segment for the three months ended September 30, 2024 and 2023 is as follows:
|  | Three Months Ended September 30, 2024 |
|  | Cell Therapy |  |  | BioBanking |  |  | Degenerative Disease |  |  | Other |  |  | Total |
Net revenues |  | $ | - |  |  | $ | 1,292 |  |  | $ | 8,004 |  |  | $ | - |  |  | $ | 9,296 |
Cost of revenues (excluding amortization of acquired intangible assets) |  |  | - |  |  |  | 238 |  |  |  | 3,645 |  |  |  | - |  |  |  | 3,883 |
Direct expenses |  |  | 3,496 |  |  |  | 353 |  |  |  | 4,187 |  |  |  | 8,529 |  |  |  | 16,565 |
Segment contribution |  | $ | (3,496 | ) |  | $ | 701 |  |  | $ | 172 |  |  | $ | (8,529 | ) |  | $ | (11,152 | )
Indirect expenses |  |  |  |  |  |  |  |  |  |  |  | 375 |  | (a) |  | 375 |
Loss from operations |  |  |  |  |  |  |  |  |  |  |  |  |  | $ | (11,527 | )
(a) Components of other |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Amortization |  |  |  |  |  |  |  |  |  |  |  | 375 |  |  |  |
Total other |  |  |  |  |  |  |  |  |  |  | $ | 375 |  |  |  |
|  | Three Months Ended September 30, 2023 |
|  | Cell Therapy |  |  | BioBanking |  |  | Degenerative Disease |  |  | Other |  |  | Total |
Net revenues |  | $ | - |  |  | $ | 1,427 |  |  | $ | 2,359 |  |  | $ | - |  |  | $ | 3,786 |
Cost of revenues (excluding amortization of acquired intangible assets) |  |  | - |  |  |  | 398 |  |  |  | 3,204 |  |  |  | - |  |  |  | 3,602 |
Direct expenses |  |  | 4,887 |  |  |  | 350 |  |  |  | 1,901 |  |  |  | 9,074 |  |  |  | 16,212 |
Segment contribution |  | $ | (4,887 | ) |  | $ | 679 |  |  | $ | (2,746 | ) |  | $ | (9,074 | ) |  | $ | (16,028 | )
Indirect expenses |  |  |  |  |  |  |  |  |  |  |  | 83,228 |  | (b) |  | 83,228 |
Loss from operations |  |  |  |  |  |  |  |  |  |  |  |  |  | $ | (99,256 | )
(b) Components of other |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Change in fair value of contingent stock consideration |  |  |  |  |  |  |  |  |  |  |  | (39 | ) |  |  |
Goodwill impairment |  |  |  |  |  |  |  |  |  |  |  | 82,714 |  |  |  |
Amortization |  |  |  |  |  |  |  |  |  |  |  | 553 |  |  |  |
Total other |  |  |  |  |  |  |  |  |  |  | $ | 83,228 |  |  |  |
Financial information by segment for the nine months ended September 30, 2024 and 2023 is as follows:
|  | Nine Months Ended September 30, 2024 |
|  | Cell Therapy |  |  | BioBanking |  |  | Degenerative Disease |  |  | Other |  |  | Total |
Net revenues |  | $ | - |  |  | $ | 3,857 |  |  | $ | 32,231 |  |  | $ | - |  |  | $ | 36,088 |
Cost of revenues (excluding amortization of acquired intangible assets) |  |  | - |  |  |  | 952 |  |  |  | 6,694 |  |  |  | - |  |  |  | 7,646 |
Direct expenses |  |  | 12,383 |  |  |  | 1,216 |  |  |  | 14,385 |  |  |  | 28,159 |  |  |  | 56,143 |
Segment contribution |  | $ | (12,383 | ) |  | $ | 1,689 |  |  | $ | 11,152 |  |  | $ | (28,159 | ) |  | $ | (27,701 | )
Indirect expenses |  |  |  |  |  |  |  |  |  |  |  | 1,377 |  | (a) |  | 1,377 |
Loss from operations |  |  |  |  |  |  |  |  |  |  |  |  |  | $ | (29,078 | )
(a) Components of other |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Amortization |  |  |  |  |  |  |  |  |  |  |  | 1,377 |  |  |  |
Total other |  |  |  |  |  |  |  |  |  |  | $ | 1,377 |  |  |  |
|  | Nine Months Ended September 30, 2023 |
|  | Cell Therapy |  |  | BioBanking |  |  | Degenerative Disease |  |  | Other |  |  | Total |
Net revenues |  | $ | - |  |  | $ | 4,062 |  |  | $ | 6,597 |  |  | $ | - |  |  | $ | 10,659 |
Cost of revenues (excluding amortization of acquired intangible assets) |  |  | - |  |  |  | 1,355 |  |  |  | 5,052 |  |  |  | - |  |  |  | 6,407 |
Direct expenses |  |  | 53,505 |  |  |  | 780 |  |  |  | 6,799 |  |  |  | 31,481 |  |  |  | 92,565 |
Segment contribution |  | $ | (53,505 | ) |  | $ | 1,927 |  |  | $ | (5,254 | ) |  | $ | (31,481 | ) |  | $ | (88,313 | )
Indirect expenses |  |  |  |  |  |  |  |  |  |  |  | 117,289 |  | (b) |  | 117,289 |
Loss from operations |  |  |  |  |  |  |  |  |  |  |  |  |  | $ | (205,602 | )
(b) Components of other |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Change in fair value of contingent consideration liability |  |  |  |  |  |  |  |  |  |  |  | (104,339 | ) |  |  |
Change in fair value of contingent stock consideration |  |  |  |  |  |  |  |  |  |  |  | (159 | ) |  |  |
Goodwill impairment |  |  |  |  |  |  |  |  |  |  |  | 112,347 |  |  |  |
IPR&D impairment |  |  |  |  |  |  |  |  |  |  |  | 107,800 |  |  |  |
Amortization |  |  |  |  |  |  |  |  |  |  |  | 1,640 |  |  |  |
Total other |  |  |  |  |  |  |  |  |  |  | $ | 117,289 |  |  |  |

X
- Definition Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 25 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-25 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30 + Details
Name: | us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_SegmentReportingAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration